论文部分内容阅读
本文收集1966年4月～1984年12月经手术和病理证实的原发性肝癌(下称肝癌)436例,对其术前血清ν-GTP 值加以分析。结果表明:1.335例(76.8%)血清ν-GTP 增高。在 AFP 阴性肝癌中86.4%(76/88)增高。2.术前ν-GTP 正常组中80.2%(81/101)可获切除,而增高组仅38.5%(129/335)。3.术中发现肝周围有转移癌或肝静脉、门静脉有癌栓的101例中,96%患者术前ν-GTP增高。4.术前ν-GTP 正常组术后生存率显著高于增高组。因此,ν-GTP 可作为诊断肝癌的重要酶标之一,而且对术前估计手术切除率、监视病情变化和预测肝癌预后也是一种有用指标。
This article collected 436 cases of primary liver cancer (hereinafter referred to as liver cancer) confirmed by surgery and pathology from April 1966 to December 1984, and analyzed preoperative serum ν-GTP values. The results showed that 1.335 (76.8%) serum ν-GTP increased. There was an increase of 86.4% (76/88) in AFP-negative liver cancer. 2. 80.2% (81/101) of the preoperative ν-GTP normal group could be removed, compared with only 38.5% (129/335) of the elevated group. 3. During the operation, 101 patients with metastases or hepatic veins around the liver and tumors in the portal vein were found. In 96% patients, preoperative ν-GTP increased. The survival rate of the preoperative ν-GTP normal group was significantly higher than that of the elevated group. Therefore, ν-GTP can be used as one of the important enzyme markers for the diagnosis of liver cancer, and it is also a useful indicator for estimating the surgical resection rate before surgery, monitoring the condition changes, and predicting the prognosis of liver cancer.